BioDelivery Sciences International (BDSI) Lowered to “Sell” at BidaskClub

BidaskClub lowered shares of BioDelivery Sciences International (NASDAQ:BDSI) from a hold rating to a sell rating in a research report released on Tuesday morning, BidAskClub reports.

A number of other equities analysts have also issued reports on the stock. Cantor Fitzgerald set a $5.00 target price on shares of BioDelivery Sciences International and gave the company a buy rating in a research report on Friday, February 15th. Janney Montgomery Scott reiterated a buy rating and issued a $5.00 target price on shares of BioDelivery Sciences International in a research report on Thursday, January 31st. SunTrust Banks started coverage on shares of BioDelivery Sciences International in a research report on Tuesday, March 19th. They issued a buy rating and a $7.00 target price for the company. HC Wainwright reiterated a buy rating and issued a $6.00 target price on shares of BioDelivery Sciences International in a research report on Friday, March 15th. Finally, Zacks Investment Research lowered shares of BioDelivery Sciences International from a strong-buy rating to a hold rating in a research report on Friday, January 11th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average price target of $5.79.

Shares of BDSI opened at $4.85 on Tuesday. The company has a quick ratio of 2.82, a current ratio of 3.07 and a debt-to-equity ratio of 1.74. BioDelivery Sciences International has a 52-week low of $1.70 and a 52-week high of $5.37.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.10). The firm had revenue of $18.03 million during the quarter, compared to analyst estimates of $16.15 million. BioDelivery Sciences International had a negative net margin of 60.87% and a negative return on equity of 79.59%. On average, equities analysts anticipate that BioDelivery Sciences International will post -0.23 EPS for the current year.

In other news, Director Healthcare Master Fun Broadfin sold 2,000,000 shares of the firm’s stock in a transaction dated Thursday, April 11th. The shares were sold at an average price of $5.00, for a total transaction of $10,000,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Francis E. Odonnell, Jr. sold 8,000 shares of the firm’s stock in a transaction dated Friday, February 1st. The shares were sold at an average price of $4.60, for a total transaction of $36,800.00. The disclosure for this sale can be found here. Insiders sold a total of 2,048,050 shares of company stock valued at $10,241,990 in the last quarter. 13.26% of the stock is currently owned by insiders.

Several large investors have recently bought and sold shares of the company. Advisor Group Inc. boosted its position in shares of BioDelivery Sciences International by 56.3% during the 4th quarter. Advisor Group Inc. now owns 10,943 shares of the specialty pharmaceutical company’s stock valued at $40,000 after purchasing an additional 3,943 shares in the last quarter. Alpha Omega Wealth Management LLC boosted its position in shares of BioDelivery Sciences International by 3.1% during the 4th quarter. Alpha Omega Wealth Management LLC now owns 156,739 shares of the specialty pharmaceutical company’s stock valued at $4,161,000 after purchasing an additional 4,677 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of BioDelivery Sciences International by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 517,620 shares of the specialty pharmaceutical company’s stock valued at $1,915,000 after purchasing an additional 5,628 shares in the last quarter. Raymond James & Associates boosted its position in shares of BioDelivery Sciences International by 14.9% during the 4th quarter. Raymond James & Associates now owns 46,211 shares of the specialty pharmaceutical company’s stock valued at $171,000 after purchasing an additional 6,000 shares in the last quarter. Finally, Vanguard Group Inc boosted its position in shares of BioDelivery Sciences International by 0.3% during the 3rd quarter. Vanguard Group Inc now owns 2,380,456 shares of the specialty pharmaceutical company’s stock valued at $6,666,000 after purchasing an additional 7,600 shares in the last quarter. Institutional investors own 57.09% of the company’s stock.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Featured Story: Dollar Cost Averaging

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.